The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Role of B Cells in Multiple Sclerosis and Related Disorders
Open accessAbstract
The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple sclerosis (MS) and primary progressive MS has led to a conceptual shift in the understanding of MS pathogenesis, away from the classical model in which T cells were the sole central actors and toward a more complex paradigm with B cells having an essential role in both the inflammatory and neurodegenerative components of the disease process. The role of B cells in MS was selected as the topic of the 27th Annual Meeting of the European Charcot Foundation. Results of the meeting are presented in this concise review, which recaps current concepts underlying the biology and therapeutic rationale behind B‐cell–directed therapeutics in MS, and proposes strategies to optimize the use of existing anti–B‐cell treatments and provide future directions for research in this area. ANN NEUROL 2021;89:13–23
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649 · cited 1×
“69 – 71 The diagnosis depends on using a reliable, speci fi c, and sensitive assay of the antibody.”
MethodNew Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 1×
“5 years in open-label extension observations, albeit with modestly favorable effects on the primary endpoint.(10,90) No evidence of progression, a novel composite endpoint tested post hoc, was also achieved more frequently in patients treated with ocrelizumab compared to placebo patients.”
BackgroundSelf-citationRuiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Self-citationLymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., Nakashima, I., Terzi, M., Totolyan, N., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 872
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain
Serafini, B., Rosicarelli, B., Franciotta, D., Magliozzi, R., Reynolds, R., Cinque, P., Andreoni, L., Trivedi, P., Salvetti, M., Faggioni, A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071030 · Cited by 766
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 734
Self-citationMyelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21617 · Cited by 560
Machado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
Self-citationAbnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Self-citationMemory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.011 · Cited by 508
Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu, C.-M., Kalled, S. L., Hess, D. M., Serafini, B., Aloisi, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041674 · Cited by 492
Self-citationRituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C. S., Michel, L., Althekair, F., Rajasekharan, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4176 · Cited by 453
Self-citationMader, S., Gredler, V., Schanda, K., Rostasy, K., Dujmovic, I., Pfaller, K., Lutterotti, A., Jarius, S., Di Pauli, F., Kuenz, B., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-184 · Cited by 449
Lublin, F., Miller, D. H., Freedman, M. S., Cree, B. A. C., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H.-P., Montalban, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Self-citationB cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
Stern, J. N. H., Yaari, G., Vander Heiden, J. A., Church, G., Donahue, W. F., Hintzen, R. Q., Huttner, A. J., Laman, J. D., Nagra, R. M., Nylander, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008879 · Cited by 441
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Self-citationMOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390
Höftberger, R., Guo, Y., Flanagan, E. P., Lopez-Chiriboga, A. S., Endmayr, V., Hochmeister, S., Joldic, D., Pittock, S. J., Tillema, J. M., Gorman, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02132-y · Cited by 369
Self-citationRituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Bar-Or, A. (2003) · Brain · doi:10.1093/brain/awg285 · Cited by 360
Self-citationRituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
Kappos, L., Hartung, H.-P., Freedman, M. S., Boyko, A., Radü, E. W., Mikol, D. D., Lamarine, M., Hyvert, Y., Freudensprung, U., Plitz, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70028-6 · Cited by 338
Self-citationPlacebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901981 · Cited by 324
Self-citationRoll, P., Palanichamy, A., Kneitz, C., Dorner, T., & Tony, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22019 · Cited by 321
Helminth infections associated with multiple sclerosis induce regulatory B cells
Correale, J., Farez, M., & Razzitte, G. (2008) · Annals of Neurology · doi:10.1002/ana.21438 · Cited by 311
Meinl, E., Krumbholz, M., & Hohlfeld, R. (2006) · Annals of Neurology · doi:10.1002/ana.20890 · Cited by 310
Self-citationConversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
Kuhle, J., Disanto, G., Dobson, R., Adiutori, R., Bianchi, L., Topping, J., Bestwick, J., Meier, U.-C., Marta, M., Costa, G. D., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514568827 · Cited by 299
Self-citationInflammatory intrathecal profiles and cortical damage in multiple sclerosis
Magliozzi, R., Howell, O. W., Nicholas, R., Cruciani, C., Castellaro, M., Romualdi, C., Rossi, S., Pitteri, M., Benedetti, M. D., Gajofatto, A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25197 · Cited by 298
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
Absinta, M., Vuolo, L., Rao, A., Nair, G., Sati, P., Cortese, I. C. M., Ohayon, J., Fenton, K., Reyes-Mantilla, M. I., Maric, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001587 · Cited by 296 · cited 1×
“Through direct correlation between MRI and pathology, it was shown that meningeal enhancement is associated with inflammation and the presence of cortical lesions.(29) Similarly, in EAE mouse models meningeal enhancement discloses areas of meningeal inflammation.”
BackgroundObermeier, B., Mentele, R., Malotka, J., Kellermann, J., Kümpfel, T., Wekerle, H., Lottspeich, F., Hohlfeld, R., & Dornmair, K. (2008) · Nature Medicine · doi:10.1038/nm1714 · Cited by 292
Self-citationMemory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
Self-citationB cell exchange across the blood-brain barrier in multiple sclerosis
von Büdingen, H.-C., Kuo, T. C., Sirota, M., van Belle, C. J., Apeltsin, L., Glanville, J., Cree, B. A., Gourraud, P.-A., Schwartzburg, A., Huerta, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63842 · Cited by 239
Self-citationMisu, T., Höftberger, R., Fujihara, K., Wimmer, I., Takai, Y., Nishiyama, S., Nakashima, I., Konno, H., Bradl, M., Garzuly, F., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1116-7 · Cited by 232
Self-citationPikor, N. B., Astarita, J. L., Summers-Deluca, L., Galicia, G., Qu, J., Ward, L. A., Armstrong, S., Dominguez, C. X., Malhotra, D., Heiden, B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.010 · Cited by 229
Palanichamy, A., Apeltsin, L., Kuo, T. C., Sirota, M., Wang, S., Pitts, S. J., Sundar, P. D., Telman, D., Zhao, L. Z., Derstine, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008930 · Cited by 225
Self-citationECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13536 · Cited by 223
Self-citationSubcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
Bar-Or, A., Grove, R. A., Austin, D. J., Tolson, J. M., VanMeter, S. A., Lewis, E. W., Derosier, F. J., Lopez, M. C., Kavanagh, S. T., Miller, A. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005516 · Cited by 219
Self-citationKaneko, K., Sato, D. K., Nakashima, I., Ogawa, R., Akaishi, T., Takai, Y., Nishiyama, S., Takahashi, T., Misu, T., Kuroda, H., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-317969 · Cited by 203
Hohlfeld, R., Dornmair, K., Meinl, E., & Wekerle, H. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00334-8 · Cited by 197
Self-citationPathogenicity of human antibodies against myelin oligodendrocyte glycoprotein
Spadaro, M., Winklmeier, S., Beltrán, E., Macrini, C., Höftberger, R., Schuh, E., Thaler, F. S., Gerdes, L. A., Laurent, S., Gerhards, R., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25291 · Cited by 196
Self-citationDeterminants of Human B Cell Migration Across Brain Endothelial Cells
Alter, A., Duddy, M., Hebert, S., Biernacki, K., Prat, A., Antel, J. P., Yong, V. W., Nuttall, R. K., Pennington, C. J., Edwards, D. R., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4497 · Cited by 195
Self-citationDistinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins
Brändle, S. M., Obermeier, B., Senel, M., Bruder, J., Mentele, R., Khademi, M., Olsson, T., Tumani, H., Kristoferitsch, W., Lottspeich, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522730113 · Cited by 190
Self-citationSecretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro
Lisak, R. P., Benjamins, J. A., Nedelkoska, L., Barger, J. L., Ragheb, S., Fan, B., Ouamara, N., Johnson, T. A., Rajasekharan, S., & Bar-Or, A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.02.015 · Cited by 180
Self-citationHohlfeld, R., Dornmair, K., Meinl, E., & Wekerle, H. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00313-0 · Cited by 180
Self-citationIntrathecal IgM synthesis is a prognostic factor in multiple sclerosis
Villar, L. M., Masjuan, J., González‐Porqué, P., Plaza, J., Sádaba, M. C., Roldán, E., Bootello, A., & Alvarez‐Cermeño, J. C. (2003) · Annals of Neurology · doi:10.1002/ana.10441 · Cited by 172
Neuromyelitis optica spectrum disorders: still evolving and broadening
Fujihara, K. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000694 · Cited by 165
Peschl, P., Schanda, K., Zeka, B., Given, K., Böhm, D., Ruprecht, K., Saiz, A., Lutterotti, A., Rostásy, K., Höftberger, R., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0984-5 · Cited by 163
Self-citationCladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Ceronie, B., Jacobs, B. M., Baker, D., Dubuisson, N., Mao, Z., Ammoscato, F., Lock, H., Longhurst, H. J., Giovannoni, G., & Schmierer, K. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8830-y · Cited by 149
B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro
Lisak, R. P., Nedelkoska, L., Benjamins, J. A., Schalk, D. L., Bealmear, B., Touil, H., Li, R., Muirhead, G., & Bar‐Or, A. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.05.004 · Cited by 135
Self-citationHäusler, D., Häusser‐Kinzel, S., Feldmann, L., Torke, S., Lepennetier, G., Bernard, C. C. A., Zamvil, S. S., Brück, W., Lehmann‐Horn, K., & Weber, M. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810470115 · Cited by 134
Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis
Beltrán, E., Gerdes, L. A., Hansen, J., Flierl‐Hecht, A., Krebs, S., Blum, H., Ertl-Wagner, B. B., Barkhof, F., Kümpfel, T., Hohlfeld, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128475 · Cited by 134
Self-citationRatelade, J., Asavapanumas, N., Ritchie, A. M., Wemlinger, S. M., Bennett, J. L., & Verkman, A. S. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1172-z · Cited by 130
Fox, E., Lovett‐Racke, A. E., Gormley, M., Liu, Y., Petracca, M., Cocozza, S., Shubin, R. A., Wray, S. E., Weiss, M., Bosco, J. A., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520918375 · Cited by 127
van Sechel, A. C., Bajramovic, J. J., van Stipdonk, M. J. B., Persoon-Deen, C., Geutskens, S. B., & van Noort, J. M. (1999) · PubMed · Cited by 123
Farina, G., Magliozzi, R., Pitteri, M., Reynolds, R., Rossi, S., Gajofatto, A., Benedetti, M. D., Facchiano, F., Monaco, S., & Calabrese, M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0812-y · Cited by 121
Anti-CD20 therapy depletes activated myelin-specific CD8 + T cells in multiple sclerosis
Sabatino, J. J., Wilson, M. R., Calabresi, P. A., Hauser, S. L., Schneck, J. P., & Zamvil, S. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915309116 · Cited by 121
Self-citationMontalbán, X., Sastre‐Garriga, J., Tintoré, M., Brieva, L., Aymerich, F., Río, J., Porcel, J., Borrás, C., Nos, C., & Rovira, À. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106937 · Cited by 117
van Sechel, A. C., Bajramovic, J. J., van Stipdonk, M. J. B., Persoon-Deen, C., Geutskens, S. B., & van Noort, J. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.129 · Cited by 115
Soltys, J., Liu, Y., Ritchie, A., Wemlinger, S. M., Schaller, K., Schumann, H., Owens, G., & Bennett, J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122942 · Cited by 105
Mariano, R., Messina, S., Kumar, K. A., Küker, W., Leite, M. I., & Palace, J. A. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12732 · Cited by 100
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
Juryńczyk, M., Jacob, A., Fujihara, K., & Palace, J. A. (2018) · Practical Neurology · doi:10.1136/practneurol-2017-001787 · Cited by 99
Targets of the humoral autoimmune response in multiple sclerosis
Fraussen, J., Claes, N., Bock, L., & Somers, V. A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.002 · Cited by 98
Hillebrand, S., Schanda, K., Nigritinou, M., Tsymala, I., Böhm, D., Peschl, P., Takai, Y., Fujihara, K., Nakashima, I., Misu, T., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1950-8 · Cited by 98
Self-citationMagliozzi, R., Hametner, S., Facchiano, F., Marastoni, D., Rossi, S., Castellaro, M., Poli, A., Lattanzi, F., Visconti, A., Nicholas, R. S., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50893 · Cited by 76
Self-citationLiu, Y., Given, K. S., Harlow, D. E., Matschulat, A. M., Macklin, W. B., Bennett, J. L., & Owens, G. P. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0428-6 · Cited by 74
Michel, L., Grasmuck, C., Charabati, M., Lécuyer, M., Zandee, S., Dhaeze, T., Alvarez, J. I., Li, R., Larouche, S., Bourbonnière, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0475 · Cited by 73
Self-citationRituximab Use in Pediatric Central Demyelinating Disease
Beres, S., Graves, J., & Waubant, E. L. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.02.007 · Cited by 69
Rejdak, K., Stelmasiak, Z., & Grieb, P. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.10.006 · Cited by 68
Cohen, M., Romero, G., Bas, J., Ticchioni, M., Rosenthal, M., Lacroix, R., Brunet, C., Rico, A., Pelletier, J., Audoin, B., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.025 · Cited by 66
Rituximab in paediatric onset multiple sclerosis: a case series
Salzer, J., Lycke, J., Wickström, R., Naver, H., Piehl, F., & Svenningsson, A. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7979-x · Cited by 64
Havrdová, E., Arnold, D. L., Bar‐Or, A., Comi, G., Hartung, H., Kappos, L., LUBLIN, F. D., Selmaj, K. W., Traboulsee, A. L., Belachew, S. M., et al. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318760642 · Cited by 60
Self-citationWolinsky, J. S., Montalbán, X., Hauser, S. L., Giovannoni, G., Vermersch, P., Bernasconi, C., Deol‐Bhullar, G., Garren, H., Chin, P., Belachew, S. M., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25313 · Cited by 60
Self-citationPediatric versus adult MS: similar or different?
Ghezzi, A., Baroncini, D., Zaffaroni, M., & Comi, G. (2017) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-017-0022-6 · Cited by 59
Self-citationDisease-modifying treatments for progressive multiple sclerosis
Comı, G. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513502572 · Cited by 57
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Barkhof, F., Kappos, L., Wolinsky, J. S., Li, D. K. B., Bar‐Or, A., Hartung, H., Belachew, S. M., Han, J., Julian, L. J., Sauter, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008189 · Cited by 57
Self-citationKim, Y., Kim, G., Shin, H.-J., Hyun, J., Kim, S. H., Lee, E. J., & Kim, H. J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1334-y · Cited by 56
Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis
Pfuhl, C., Grittner, U., Gieß, R. M., Scheel, M., Behrens, J. R., Rasche, L., Pache, F. C., Wenzel, R., Brandt, A. U., Bellmann–Strobl, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008237 · Cited by 55
for the Canadian B Cell Team in MS, Touil, H., Kobert, A., Lebeurrier, N., Rieger, A. M., Saikali, P., Lambert, C., Fawaz, L. M., Moore, C. S., Prat, A., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1136-2 · Cited by 54
Self-citationTur, C., Montalban, X., Tintoré, M., Nos, C., Río, J., Aymerich, F. X., Brieva, L., Téllez, N., Perkal, H., Comabella, M., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.241 · Cited by 53
Self-citationIntrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study
Bergman, J., Burman, J., Gilthorpe, J. D., Zetterberg, H., Jiltsova, E., Bergenheim, T. A., & Svenningsson, A. (2018) · Neurology · doi:10.1212/wnl.0000000000006500 · Cited by 43
Larsson, D., Åkerfeldt, T., Carlson, K. E., & Burman, J. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519863983 · Cited by 35
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study
Cellerino, M., Ivaldi, F., Pardini, M., Rotta, G., Vila, G., Bäcker‐Koduah, P., Berge, T., Laroni, A., Lapucci, C., Novi, G., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000693 · Cited by 27
Self-citationPol, S. U., Schweser, F., Bertolino, N., Preda, M., Sveinsson, M., Sudyn, M. L., Babek, N., & Zivadinov, R. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.01.013 · Cited by 26
CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis
Bensalem, A., Mulleman, D., Thibault, G., Azzopardi, N., Goupille, P., Paintaud, G., & Ternant, D. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14102 · Cited by 17
Progress in Multiple Sclerosis Research
Hauser, S. L. (2020) · JAMA · doi:10.1001/jama.2020.1522 · Cited by 12
Self-citationCasanova, B., Lacruz, L., Villar, M. L., Domínguez, J. A., Carcelén‐Gadea, M., Gascón, F., Mallada, J. J., Hervás, D., Simó, M., Alvarez-Cermeño, J. C., et al. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3442-y · Cited by 8
Imaging of meningeal inflammation should become part of the routine MRI protocol – Yes
Absinta, M., & Reich, D. S. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518794082 · Cited by 5
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Cited by
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 507
Self-citationBruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Self-citationT–B cell cooperation in ectopic lymphoid follicles propagates CNS autoimmunity
Kolz, A., de la Rosa, C., Syma, I. J., McGrath, S., Kavaka, V., Schmitz, R., Thomann, A. S., Kerschensteiner, M., Beltran, E., Kawakami, N., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adn2784 · Cited by 20
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
Metadata
- Authors
- Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-11-04
- Volume
- 89
- Issue
- 1
- Pages
- 13-23
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3092316673
- Cited by
- 283
- References
- 103
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.